OBJECTIVES: To identify factors associated with sustained undetectable viraemia after HIV-1 seroconversion in treatment-naive patients, and to describe concomitant CD4 cell count progression. METHODS: Seroconverters enrolled in CASCADE were assumed to control viraemia if at least two consecutive viral load measurements were < 400/500 copies/ml without treatment. Factors associated with undetectable viraemia were identified through a logistic regression. A joint model was used to describe simultaneously the CD4 cell count progression during and after that period and to identify factors associated with sustained undetectable viraemia. RESULTS: Of 2176 seroconverters, 145 (6.7%) spontaneously controlled viraemia. Women were more likely than men to achieve undetectable viraemia [adjusted odds ratio (OR), 2.12; 95% confidence interval (CI), 1.49-3.12] unlike patients who reported a symptomatic primary infection (adjusted OR, 0.58; 95% CI, 0.36-0.94). AIDS and death rates were significantly lower in patients achieving undetectable viraemia than in the others. The median period of undetectable viraemia was 11.2 months; on average, CD4 cell counts remained stable during that period, and decreased with a mean rate of 5 cells/microl per month thereafter. High CD4 cell count at the beginning of undetectable viraemia and non-symptomatic primary infection favoured the preservation of undetectable viraemia. CONCLUSION: A small proportion of seroconverters appeared to be able to control HIV viraemia spontaneously, mostly those without seroconversion illness and within a few years following seroconversion; this is associated with the benefits of slower CD4 cell count decline and improved long-term prognosis. Such persons should be targeted for in depth investigation.
OBJECTIVES: To identify factors associated with sustained undetectable viraemia after HIV-1 seroconversion in treatment-naive patients, and to describe concomitant CD4 cell count progression. METHODS: Seroconverters enrolled in CASCADE were assumed to control viraemia if at least two consecutive viral load measurements were < 400/500 copies/ml without treatment. Factors associated with undetectable viraemia were identified through a logistic regression. A joint model was used to describe simultaneously the CD4 cell count progression during and after that period and to identify factors associated with sustained undetectable viraemia. RESULTS: Of 2176 seroconverters, 145 (6.7%) spontaneously controlled viraemia. Women were more likely than men to achieve undetectable viraemia [adjusted odds ratio (OR), 2.12; 95% confidence interval (CI), 1.49-3.12] unlike patients who reported a symptomatic primary infection (adjusted OR, 0.58; 95% CI, 0.36-0.94). AIDS and death rates were significantly lower in patients achieving undetectable viraemia than in the others. The median period of undetectable viraemia was 11.2 months; on average, CD4 cell counts remained stable during that period, and decreased with a mean rate of 5 cells/microl per month thereafter. High CD4 cell count at the beginning of undetectable viraemia and non-symptomatic primary infection favoured the preservation of undetectable viraemia. CONCLUSION: A small proportion of seroconverters appeared to be able to control HIV viraemia spontaneously, mostly those without seroconversion illness and within a few years following seroconversion; this is associated with the benefits of slower CD4 cell count decline and improved long-term prognosis. Such persons should be targeted for in depth investigation.
Authors: Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson Journal: J Virol Date: 2010-05-05 Impact factor: 5.103
Authors: Philomena Kamya; Christos M Tsoukas; Salix Boulet; Jean-Pierre Routy; Réjean Thomas; Pierre Côté; Mohamed-Rachid Boulassel; Bernard Lessard; Rupert Kaul; Mario Ostrowski; Colin Kovacs; Cecile L Tremblay; Nicole F Bernard Journal: AIDS Res Ther Date: 2011-06-16 Impact factor: 2.250
Authors: Iris Chen; Vanessa Cummings; Jessica M Fogel; Mark A Marzinke; William Clarke; Matthew B Connor; Sam Griffith; Susan Buchbinder; Steven Shoptaw; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Christopher W Pohlmeyer; Veronica D Gonzalez; Alivelu Irrinki; Ricardo N Ramirez; Li Li; Andrew Mulato; Jeffrey P Murry; Aaron Arvey; Rebecca Hoh; Steven G Deeks; George Kukolj; Tomas Cihlar; Stefan Pflanz; Garry P Nolan; Gundula Min-Oo Journal: J Virol Date: 2019-03-21 Impact factor: 5.103
Authors: Benoît Vingert; Santiago Perez-Patrigeon; Patricia Jeannin; Olivier Lambotte; Faroudy Boufassa; Fabrice Lemaître; William W Kwok; Ioannis Theodorou; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti Journal: PLoS Pathog Date: 2010-02-26 Impact factor: 6.823